Medicines

Use this search to find information on specific human, veterinary and herbal medicines published on the European Medicines Agency’s (EMA) website. Alternatively, you can use the site-wide search in the header above to search across all the content on the EMA website. The regulatory sections of the website contain information on medicines under evaluation, medicine shortages, medication errors, medicines for use outside the European Union (EU) and post-authorisation safety studies.

Versican Plus Pi

canine parainfluenza virus vaccine (live attenuated)

Opinion

On 13 September 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisations for the veterinary medicinal products Versican Plus DHPPi/L4R, Versican Plus DHPPi/L4, Versican Plus DHPPi, Versican Plus Pi/L4R, Versican Plus Pi/L4, Versican Plus Pi and Versican Plus L4. The marketing authorisation holder for these veterinary medicinal products is Zoetis Belgium S.A.

Versican Plus DHPPi/L4R, Versican Plus DHPPi/L4, Versican Plus Pi/L4R, Versican Plus Pi/L4 and Versican Plus Pi are currently authorised as lyophilisate and suspension for suspension for injection. Versican Plus DHPPi and Versican Plus Pi are currently authorised as lyophilisate and solvent for suspension for injection.Versican Plus L4 is currently authorised as suspension for injection. The variation concerns the inclusion of data regarding the use of Versican Plus range vaccines during pregnancy. The variation introduces changes to the summary of product characteristics (SPC) and other product information. The product information has been simultaneously aligned with the latest quality review of documents (QRD) template v.8.1.

Detailed conditions for the use of these products are described in the updated summary of product characteristics (SPC), for which updated versions reflecting the changes will be published in the revised European public assessment reports (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisations has been granted by the European Commission.


1 Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Key facts

Name
Versican Plus Pi
International non-proprietary name (INN) or common name
  • canine parainfluenza virus vaccine (live attenuated)
Species
Dogs
Active substance
  • canine parainfluenza type-2 virus, strain CPiV-2 Bio 15 (live attenuated)
Date opinion adopted
13/09/2018
Company name
Zoetis Belgium SA
Status
Positive
Application type
Post-authorisation

Related content

How useful was this page?

Add your rating